Toggle Main Menu Toggle Search

Open Access padlockePrints

Gastro-protective effects of isobrucein B, a quassinoid isolated from Picrolemma sprucei

Lookup NU author(s): Dr Henrique De Paula Lemos

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Infusions of Picrolemma sprucei roots, stems and leaves are used in traditional medicine throughout the Amazon region from the Guianas to Brazil and Peru in the treatment of gastritis, intestinal helminths and malaria. As there are no studies describing its mode of action in providing a gastroprotective effect, we determined herein that one of the main constituents found in P. sprucei infusions, the quassinoid isobrucein B (IsoB), reduces some of the pathophysiological effects in a mouse model of non-steroidal anti-inflammatory drug (NSAID)-induced gastritis and provides mechanisms of action. Then, IsoB (1.17 g) was isolated from the roots and stems (6.5 kg) of P. sprucei. Its structure was confirmed by 1D and 2D (1)H and (13)C NMR, ESI-tof-MS, IR and UV. C57BL/6 strain mice were subcutaneously injected with IsoB (0.5-5 mg kg(-1)) or vehicle before oral administration of indomethacin and sacrificed later at different time points. Gastric damage was assessed by measuring lesion length. Leukocyte migration was evaluated based on leukocyte rolling and adhesion using intravital microscopy in the mesenteric microcirculation and tissue MPO activity. Stomach extract cytokine (TNFα, IL-1β and KC/CXCL1) and prostaglandin E2 (PGE2) levels were measured by ELISA and RIA, respectively. IsoB pre-treatment (0.5-5.0 mg kg(-1)) significantly reduced the formation of indomethacin-induced stomach lesions in a dose-dependent manner. The decrease in stomach lesions was associated with less observed leukocyte rolling, decreased leukocyte adhesion and less neutrophil infiltration (MPO activity). IsoB (1 mg kg(-1)) pre-treatment did not prevent indomethacin-induced decreases in stomach PGE2 levels. However, IL-1β and KC/CXCL1 levels were inhibited by this same IsoB dosage, whereas TNF-α was unchanged. IsoB may be a prototypic compound to provide protective effects against NSAID-induced gastritis and possibly other gastropathies. Moreover, IsoB gastroprotective action may be due to a reduction in IL-1β and KC/CXCL1 production/release and leukocyte rolling, adhesion and migration.


Publication metadata

Author(s): Vieira SM, Silva RL, Lemos HP, Amorim RC, Silva EC, Reinach PS, Cunha FQ, Pohlit AM, Cunha TM

Publication type: Article

Publication status: Published

Journal: Fitoterapia

Year: 2014

Volume: 95

Pages: 8-15

Print publication date: 01/06/2014

Online publication date: 01/03/2014

Acceptance date: 01/03/2014

ISSN (print): 1971-551X

ISSN (electronic): 0367-326X

Publisher: Elsevier

URL: http://doi.org/10.1016/j.fitote.2014.02.008

DOI: 10.1016/j.fitote.2014.02.008

PubMed id: 24594240


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share